News
$Insmed (INSM.US)$ Insmed Says Phase 3 Study Achieves Primary Endpoint For Both Dosage Strengths Of Brensocatib With Statistically Significant, Clinically Meaningful Reduction In Frequency Of Pulmonary Exacerbations Versus Placebo
Benzinga· 2 mins ago
Benzinga· 2 mins ago
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
